Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Breast Neoplasms, Male × elacestrant × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 12 Advanced Breast Cancer 2 Recurrence 1 Neoplasms by Site 1 Neoplasms 1 Neoplasm Metastasis 1 Endometrial Neoplasms 1 ESR1 Gene Mutation 1 ER+ Breast Cancer 1 Central Nervous System Neoplasms 1 Central Nervous System Diseases 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Neoplasms, Male 1 Breast Diseases 1 Brain Neoplasms 1 Brain Diseases 1

Interventions

ribociclib 2 exemestane 2 abemaciclib 2 Tamoxifen 2 Letrozole 2 Anastrozole 2 palbociclib 1 elacestrant 1 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 Standard of Care 1 Practice Guidelines as Topic 1 Methods 1 Leuprolide 1 Interviews as Topic 1 Goserelin 1 Genetic Counseling 1 Educational Status 1 Early Intervention, Educational 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06492616 2026-03-27

ELEGANT

Stemline Therapeutics, Inc.

Phase 3 Recruiting

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon ⚡